[Pegabalin and congenital abnormalities]

Area of Science:

• Pharmacovigilance
• Obstetrics
• Teratology

Background:

• Pregabalin is commonly prescribed for neuropathic pain, anxiety, and epilepsy.
• Regulatory agencies have advised against pregabalin use in pregnant women based on a European study.
• Concerns exist regarding potential risks of major congenital malformations from first-trimester in utero exposure.

Purpose of the Study:

• To re-evaluate the safety of pregabalin use during pregnancy.
• To analyze the available data on pregabalin exposure in pregnant women.
• To assess the risk of major congenital malformations associated with first-trimester pregabalin exposure.

Main Methods:

• Analysis of a study conducted in four European countries.
• Comprehensive evaluation of existing data on pregabalin in pregnant women.
• Critical review of regulatory interpretations regarding teratogenic risks.

Main Results:

• The study's findings were interpreted alarmingly by some agencies.
• Our re-analysis and overall data evaluation do not support an increased risk of major congenital malformations.
• Pregabalin's safety profile in pregnancy requires a nuanced interpretation.

Conclusions:

• The perceived risk of major congenital malformations with first-trimester pregabalin exposure may be overestimated.
• Current data do not conclusively demonstrate a significant teratogenic risk.
• Further research and careful consideration of individual patient needs are warranted for pregnant women using pregabalin.